Yiling Pharmaceutical Withdraws Clinical Filing for G201-Na in Assisted Reproduction
China-based Yiling Pharmaceutical Co., Ltd (SHE: 002603) has announced the withdrawal of its clinical filing...
Yiling Pharmaceutical
Youjia Biomedical and Yiling Pharmaceutical Collaborate on RNAi Metabolic Disease Treatments
China-based Youjia (Hangzhou) Biomedical Technology Co., Ltd, a leading nucleic acid technology developer, has entered...
Yiling Pharmaceutical Gains NMPA Approval for XY0206 in AML Trial
China-based Yiling Pharmaceutical Co., Ltd (SHE: 002603) has announced that it has received clinical trial...
Yiling Pharmaceutical Secures NMPA Approval for Phase I Study of G201-Na in Premenopausal Women
China-based Yiling Pharmaceutical Co., Ltd (SHE: 002603) has announced that it has received approval from...
Yiling Pharmaceutical’s XY0206 Advances to Phase III Trial for FLT3-ITD AML
China-based Yiling Pharmaceutical Co., Ltd (SHE: 002603) has announced its plans to initiate a Phase...
Yiling Pharmaceutical’s G201-Na Receives CDE Approval for Phase Ia Study in Prostate Cancer Treatment
China-based Yiling Pharmaceutical Co., Ltd (SHE: 002603) has announced receiving approval from the Center for...
Yiling Pharmaceutical’s BIO-008 Receives NMPA Approval for Clinical Trials
China-based Yiling Pharmaceutical Co., Ltd (SHE: 002603) has announced that it has received clinical trial...
Yiling Pharmaceutical’s G201-Na Accepted for Review by China’s NMPA for Prostate Cancer
China-based Yiling Pharmaceutical Co., Ltd (SHE: 002603) has announced that its clinical trial filing for...
Yiling Pharmaceutical’s BIO-008 Accepted for Review by China’s NMPA
China-based Yiling Pharmaceutical Co., Ltd (SHE: 002603) has announced that its clinical trial filing for...